Veradigm Inc.

Equities

MDRX

US01988P1084

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 03:59:59 2024-05-10 pm EDT			5-day change	1st Jan Change
7.79 ^USD	+0.52%		+1.17%	-25.74%

Apr. 03	Veradigm and Vim Announce Strategic Collaboration to Improve Payer-Provider Collaboration	CI
Mar. 19	Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15	MT

Allscripts Healthcare Solutions, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2021

January 24, 2022 at 04:01 pm EST

Allscripts Healthcare Solutions, Inc. provided earnings guidance for the fourth quarter and full Year 2021. For the fourth quarter of 2021, revenue is expected to be between $390 million and $395 million.

For the full year 2021, the company expects GAAP operating income to be between $70 million and $75 million.

Latest news about Veradigm Inc.

Veradigm and Vim Announce Strategic Collaboration to Improve Payer-Provider Collaboration	Apr. 03	CI
Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15	Mar. 19	MT
Transcript : Veradigm Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM	Mar. 13
Veradigm Inc. Provides Earnings Guidance for the Fiscal Year 2024	Mar. 13	CI
Veradigm Inc. completed the acquisition of Cascade Bio, Inc	Mar. 03	CI
Veradigm Inc.(OTCPK:MDRX) dropped from S&P 600 Health Care	Mar. 03	CI
Veradigm Inc.(OTCPK:MDRX) dropped from S&P 600	Mar. 03	CI
Veradigm Inc.(OTCPK:MDRX) dropped from S&P Composite 1500	Mar. 03	CI
Veradigm Inc.(OTCPK:MDRX) dropped from S&P Global BMI Index	Mar. 03	CI
Veradigm Inc.(OTCPK:MDRX) dropped from S&P 1000	Mar. 03	CI
Veradigm Inc.(OTCPK:MDRX) dropped from S&P TMI Index	Mar. 03	CI
Veradigm Inc.(OTCPK:MDRX) dropped from NASDAQ Composite Index	Feb. 27	CI
Veradigm to Buy ScienceIO for $140 Million; Expects Nasdaq Delisting Notice; Shares Fall	Feb. 27	MT
Veradigm Inc. signed a definitive agreement to acquire Cascade Bio, Inc.	Feb. 26	CI
Veradigm Inc. and Veradigm LLC Enter into an Amendment to the Third Amended and Restated Credit Agreement	Jan. 31	CI
RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating	Jan. 19	MT
Transcript : Veradigm Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM	Jan. 10
Veradigm Expects Lower Fiscal 2023 Non-GAAP Earnings, Revenue	Jan. 10	MT
Veradigm Inc. Revises Earnings Guidance for the Fiscal 2023	Jan. 10	CI
Veradigm Picks MedAllies as Qualified Health Information Network Partner	Jan. 09	MT
Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target	Jan. 03	MT
Veradigm Acquires Koha Health	Jan. 02	MT
Veradigm Inc. acquired Koha Health, LLC.	Jan. 01	CI
Wall Street Futures Lean Lower Premarket Thursday; Volumes Remain Thin Towards Year-End	Dec. 28	MT
Veradigm to Continue to Be Listed Subject to Demonstrating Compliance With Nasdaq Rules	Dec. 13	MT

Chart Veradigm Inc.

Duration

Period

More charts

Company Profile

Veradigm Inc. is a healthcare data and technology solutions technology company. The Company is focused on research, analytics, and building scalable data-driven solutions. It combines data-driven clinical insights with actionable tools to enable healthcare stakeholders improve the value of healthcare delivery. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. Its Veradigm Network Solutions include Veradigm Real World Data, Veradigm Real World Evidence, Veradigm Digital Health Media, and Evalytica. Its health plan and payer solutions include eCHART COURIER, Veradigm Payer Insights, and Risk Adjustment & Quality Analytics. Its healthcare provider solutions include Veradigm Practice Management, Veradigm Payerpath, and Electronic Health Records. It also provides full-service revenue cycle management.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.79 USD

Average target price

15 USD

Spread / Average Target

+92.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
VERADIGM INC.	-25.74%	839M
VEEVA SYSTEMS INC.	+5.85%	32.93B
PRO MEDICUS LIMITED	+20.16%	7.94B
SECTRA AB	+30.81%	4.19B
EVOLENT HEALTH, INC.	-25.95%	2.8B
OMNICELL, INC.	-19.96%	1.38B
LUNIT INC.	-31.87%	1.17B
SIMULATIONS PLUS, INC.	+8.02%	966M
B-SOFT CO.,LTD.	-35.73%	900M
SURGICAL SCIENCE SWEDEN AB	-20.05%	687M

Medical Software & Technology Services